Buy or sell Humacyte stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Humacyte Stock

Humacyte develops products for vascular diseases and replacement of anatomical conduits.

About Humacyte Stock

Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Funding History

November 2009$7.0M
September 2010$12.0M
January 2015$49.8M
October 2015$150M
August 2016$10.0M
September 2017$14.1M
March 2018$75.0M

Management

Co-Founder and VP

Juliana L. Blum

CEO

Carrie Cox

COO

Theodore D. Lithgow

CMO

Alison Pilgrim

CFO

Paul Boyer

Founder & CTO

Laura E. Niklason

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Humacyte or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 80K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo